Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$2.27
+7.1%
$1.86
$1.42
$12.33
$83.25M1.34612,520 shs1.16 million shs
NeurAxis, Inc. stock logo
NRXS
NeurAxis
$2.61
+0.4%
$2.29
$1.33
$6.20
$18.83M3.35411,283 shs156,746 shs
InspireMD, Inc. stock logo
NSPR
InspireMD
$2.50
$2.53
$2.07
$3.80
$76.59M0.5938,917 shs86,105 shs
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$4.92
-2.2%
$4.63
$4.01
$9.33
$80.91M1.3201,020 shs42,737 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
+7.08%+11.82%+28.98%+16.41%-77.59%
NeurAxis, Inc. stock logo
NRXS
NeurAxis
+0.38%-4.40%+25.18%+20.00%-19.44%
InspireMD, Inc. stock logo
NSPR
InspireMD
0.00%-1.19%-2.11%-11.97%-7.41%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
-2.19%+3.36%+16.59%+6.96%-14.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.9174 of 5 stars
3.30.00.04.30.60.01.3
NeurAxis, Inc. stock logo
NRXS
NeurAxis
1.5981 of 5 stars
0.05.00.00.03.32.50.0
InspireMD, Inc. stock logo
NSPR
InspireMD
2.8381 of 5 stars
3.55.00.00.00.62.50.6
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
1.9779 of 5 stars
3.61.00.00.02.40.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.50
Moderate Buy$9.75329.52% Upside
NeurAxis, Inc. stock logo
NRXS
NeurAxis
0.00
N/AN/AN/A
InspireMD, Inc. stock logo
NSPR
InspireMD
3.00
Buy$4.5080.00% Upside
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3.25
Buy$11.67137.13% Upside

Current Analyst Ratings Breakdown

Latest NRXS, NSPR, SRTS, and INO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $10.00
5/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$5.00 ➝ $5.00
5/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $13.00
5/12/2025
InspireMD, Inc. stock logo
NSPR
InspireMD
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.00
4/4/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
3/19/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$6.00 ➝ $5.00
3/19/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.00
3/11/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $13.00
(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$283.10K294.07N/AN/A$5.16 per share0.44
NeurAxis, Inc. stock logo
NRXS
NeurAxis
$2.93M6.42N/AN/A($0.27) per share-9.67
InspireMD, Inc. stock logo
NSPR
InspireMD
$7.03M10.90N/AN/A$1.83 per share1.37
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$39.49M2.05$0.05 per share96.29$2.98 per share1.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$135.12M-$3.19N/AN/AN/AN/A-118.17%-83.47%8/14/2025 (Estimated)
NeurAxis, Inc. stock logo
NRXS
NeurAxis
-$14.63M-$1.19N/AN/A-492.76%N/A-641.25%N/A
InspireMD, Inc. stock logo
NSPR
InspireMD
-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$6.65M$0.1012.3021.39N/A15.90%12.60%11.38%8/14/2025 (Estimated)

Latest NRXS, NSPR, SRTS, and INO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.04-$0.16-$0.20-$0.16$7.23 million$8.34 million
5/13/2025Q1 2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.74-$0.51+$0.23-$0.51$0.01 million$0.07 million
3/18/2025Q4 2024
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.87-$0.69+$0.18-$0.60$0.03 million$0.12 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
NeurAxis, Inc. stock logo
NRXS
NeurAxis
N/AN/AN/AN/AN/A
InspireMD, Inc. stock logo
NSPR
InspireMD
N/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
3.88
3.88
NeurAxis, Inc. stock logo
NRXS
NeurAxis
N/A
0.24
0.23
InspireMD, Inc. stock logo
NSPR
InspireMD
N/A
6.39
6.05
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/A
10.52
7.89

Institutional Ownership

CompanyInstitutional Ownership
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
NeurAxis, Inc. stock logo
NRXS
NeurAxis
11.77%
InspireMD, Inc. stock logo
NSPR
InspireMD
44.78%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
25.30%

Insider Ownership

CompanyInsider Ownership
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.30%
NeurAxis, Inc. stock logo
NRXS
NeurAxis
15.20%
InspireMD, Inc. stock logo
NSPR
InspireMD
34.06%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
8.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
32036.67 million25.45 millionOptionable
NeurAxis, Inc. stock logo
NRXS
NeurAxis
197.22 million6.09 millionNot Optionable
InspireMD, Inc. stock logo
NSPR
InspireMD
5030.64 million18.33 millionOptionable
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
4016.45 million14.85 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$2.27 +0.15 (+7.08%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$2.27 0.00 (0.00%)
As of 06/6/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

NeurAxis stock logo

NeurAxis NASDAQ:NRXS

$2.61 +0.01 (+0.38%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$2.66 +0.05 (+2.07%)
As of 06/6/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

InspireMD stock logo

InspireMD NYSE:NSPR

$2.50 0.00 (0.00%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$2.54 +0.04 (+1.76%)
As of 06/6/2025 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Sensus Healthcare stock logo

Sensus Healthcare NASDAQ:SRTS

$4.92 -0.11 (-2.19%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$5.19 +0.27 (+5.47%)
As of 06/6/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.